Daily Squeeze Report
The top short-squeeze candidates among US-listed equities, published daily from authoritative FINRA short-interest data.
- November 20, 2026
Squeeze Report — November 20, 2026
Biotech dominates today's crowded-short slate, but the setups worth watching are binary catalysts, not borrow mechanics: CAPR's FDA decision on Saturday and SMMT's overdue PDUFA could produce violent two-way moves. Elsewhere, WOLF's 90% short interest is a dilution trap in disguise.
Read the report → - November 19, 2026
Squeeze Report — November 19, 2026
No high-conviction squeeze setups today. AESI is the only name with real short interest and a near-term catalyst, but weak borrow mechanics and a heavy balance sheet blunt the edge. Everything else is either drifting, diluting, or waiting on catalysts months away.
Read the report → - November 18, 2026
Squeeze Report — November 18, 2026
No high-conviction squeezes on today's board, but the real story is the cluster of stale short-interest prints colliding with heavy dilution events — CVI's Marathon financing, AAOI's $550M ATM, and SUPN's Indivior close all expand float right as bears ease off.
Read the report → - November 17, 2026
Squeeze Report — November 17, 2026
The board splits into two camps today: binary FDA/regulatory plays (CAPR, VERA, WOLF) where a single headline could force covering, and high-short-interest names where the fuel is already decaying as shorts quietly exit. The most interesting setups are those where hard catalysts meet cheap borrow and crowded options—conditions that favor sharp, fade-prone spikes.
Read the report → - November 16, 2026
Squeeze Report — November 16, 2026
The tape is crowded with heavily shorted names that have already run or are pinned near lows, but almost none have tight borrow. The real tension is between stale short-interest optics and fresh covering — with catalysts like KSS earnings and ASH data deciding which way the overhang breaks.
Read the report → - November 13, 2026
Squeeze Report — November 13, 2026
CSIQ tops the short-squeeze leaderboard for November 13, 2026 with 41% of its float sold short. 15 names scored in the hot zone (≥80) across 15 ranked tickers.
Read the report → - November 12, 2026
Squeeze Report — November 12, 2026
Today's tape splits between names riding momentum into crowded positioning (TIC, ABSI) and broken industrials where shorts are already covering into bad news (FLNC, ARRY). The cleanest squeeze setups are absent — cheap borrow and declining short bases undercut most of the high scores.
Read the report → - November 11, 2026
Squeeze Report — November 11, 2026
No high-conviction squeeze setups made the cut today — the tape is a wall of 'low' verdicts. The most interesting cluster is the handful of medium-potential small caps (AADX, AEHR, ADMA) where real short interest meets thin floats but no immediate catalyst, making them coiled rather than triggered.
Read the report → - November 10, 2026
Squeeze Report — November 10, 2026
Biotech dominates today's actionable squeeze board, with ACHV, CAPR, SVRA and SLS all carrying binary FDA or data catalysts into year-end. Outside the sector, CRK's $1.65B asset sale and FOUR's fresh buyback offer the cleanest event-driven setups, while several high-short names like FLNC and VYX look already spent.
Read the report → - November 9, 2026
Squeeze Report — November 9, 2026
Biotech and small-cap earnings dominate today's slate, with TNGX, SRRK, CRMD, and IBRX all reporting within 72 hours — several into crowded options positioning that may blunt any squeeze. Separately, CLBK and XXI show how stale short-interest data can inflate a squeeze score into a trap.
Read the report → - November 6, 2026
Squeeze Report — November 6, 2026
The tape splits between catalyst-driven setups and stale short-interest mirages. Comstock's $1.65B asset-sale close and Replimune's TUDRIQEV launch give shorts a hard deadline, while names like METC and TAL carry extreme float short but no trigger.
Read the report → - November 5, 2026
Squeeze Report — November 5, 2026
The squeeze tape is bifurcated: ARRY and ACHV offer live, catalyst-driven setups with real short fuel, while the rest of the board shows classic event-risk fade patterns. The strongest names cluster around earnings and M&A triggers, but nearly every high-short-interest story is undermined by cheap borrow and ample availability.
Read the report → - November 4, 2026
Squeeze Report — November 4, 2026
Tomorrow's tape is a coin-flip on beaten-down retail and small-cap earnings: PTLO, AAP, and AAOI all report into elevated short interest, while EBS simmers on a debt-refinancing catalyst. Elsewhere, the squeeze screen is mostly noise — large-cap tech and legacy industrials show empty short bases.
Read the report → - November 3, 2026
Squeeze Report — November 3, 2026
The tape is bifurcated: a cluster of Nov 5 earnings catalysts (KRMN, LION, ENOV, FOUR, TNDM) collides with a consumer/meme rotation that is starving healthcare and tech of squeeze fuel. BYND is the standout — scarce, expensive borrow plus an imminent binary print makes it the only high-conviction mechanical setup on the board.
Read the report → - November 2, 2026
Squeeze Report — November 2, 2026
TGTX is the marquee setup: a 52-week high, 21% of float short, and a binary Q3 earnings catalyst on the same day. Clustering is heavy in biotech, where AVTX, SLS, VERA, and XNCR all offer event-driven squeeze potential, while energy and consumer names cool.
Read the report → - October 30, 2026
Squeeze Report — October 30, 2026
Biotech earnings dominate the board, but the real tension is between stale short-interest optics and live borrow markets. Names like XNCR, NAMS, and REPL flash high SI% on paper while shorts already cut and fees stay cheap — classic fade-risk setups. The higher-conviction mechanical squeezes, like CRSR and SEI, face crowded options and dilution overhangs that cap upside.
Read the report → - October 29, 2026
Squeeze Report — October 29, 2026
The screen is crowded with high short interest and thin floats, but the actual pressure points are scattered: NNE's NRC milestone is months away, while a cluster of Q3 earnings — SVV, ACHC, QDEL, TNGX — hits within days. PRME's 54% short float after a 75% run is the most volatile setup on the board.
Read the report → - October 28, 2026
Squeeze Report — October 28, 2026
Short interest is high across today's board, but the tape is telling a different story: many of these names are falling knives where shorts are already covering or borrow remains cheap. The real outliers are the tiny-float spins and pre-earnings biotechs — MMED, CSIQ, VERA — where a single print could force a violent unwind.
Read the report → - October 27, 2026
Squeeze Report — October 27, 2026
The squeeze radar today is dominated by event-driven setups ahead of Q3 earnings, but almost none of them show real borrow stress. The notable exceptions are the pre-revenue biotech/nuclear cluster — IBRX, NNE, XNCR — where dilution overhangs are fighting against structurally trapped shorts.
Read the report → - October 26, 2026
Squeeze Report — October 26, 2026
Earnings season is compressing a crowded short base into a series of binary events, but the tape is already paying for volatility. The most interesting setups aren't the highest short interest — they're the names where stale shorts meet fresh, unpriced catalysts.
Read the report → - October 23, 2026
Squeeze Report — October 23, 2026
The pre-election earnings calendar is colliding with a crowded short base across software, consumer, and biotech. The highest-conviction setups aren't the biggest short interest numbers — they're names where a single Q3 print could force covering in days, not weeks.
Read the report → - October 22, 2026
Squeeze Report — October 22, 2026
The tape splits between names with textbook squeeze math and ones where the bear case is winning. Frontier's Oct 28 print is the cleanest event — 24% short, near-breakeven consensus, and a binary catalyst — while TAL's 40% short interest looks like a trap without a borrow squeeze.
Read the report → - October 21, 2026
Squeeze Report — October 21, 2026
The book is crowded with pre-earnings squeeze candidates, but the real split is between clean technical setups and names where dilution or deteriorating fundamentals poison the fuel. LION and TNDM stand out as the highest-conviction two-sided bets into early-November prints.
Read the report → - October 20, 2026
Squeeze Report — October 20, 2026
The tape is split between crowded biotech shorts and fading retail/legacy shorts. NEO's 60% float short into October 28 earnings is the headline setup, while HRB's 68–79% daily short volume ahead of November 5 makes it the stealth event.
Read the report → - October 19, 2026
Squeeze Report — October 19, 2026
GLOB tops the short-squeeze leaderboard for October 19, 2026 with 31% of its float sold short. 2 names scored in the hot zone (≥80) across 15 ranked tickers.
Read the report → - October 16, 2026
Squeeze Report — October 16, 2026
The squeeze screen is bifurcated: a cluster of consumer and energy names (KSS, ULCC, BKV) hold live but late-stage setups into earnings, while biotech's crowded unwind leaves mechanically high short interest (ORIC, BEAM, VSTM) looking like traps, not fuel. The edge today is in names where the borrow is still cheap but the catalyst is hard-dated.
Read the report → - October 15, 2026
Squeeze Report — October 15, 2026
The tape is bifurcated: TAL and SEI show genuine squeeze fuel, but most of today's high-short-interest names are undermined by cheap borrow, dilution, or insider selling. The recurring theme is a market regime rotating away from biotech and speculative tech, leaving static short-interest screens looking hollow.
Read the report → - October 14, 2026
Squeeze Report — October 14, 2026
Two biotechs with 40%+ short interest — TNGX and CSIQ — frame today's book, but conviction is capped by dilution and cheap borrow. The more interesting tension sits in MMED, where a Medtronic split-off could force a violent, short-lived cover into a float that expands tenfold days later.
Read the report → - October 13, 2026
Squeeze Report — October 13, 2026
The tape is bifurcated: extreme float math in MMED (99% short) and IBRX (109% short) sits atop real bear cases, while earnings-driven setups in SEI, HOG, and CAKE cluster around late-October catalysts. The squeeze case is strongest where the borrow has already broken, not where shorts can still wait cheaply.
Read the report → - October 12, 2026
Squeeze Report — October 12, 2026
The squeeze tape is bifurcated: commodity and legacy retail shorts (CRK, GO, KSS) are trapped by weak fundamentals, while pre-catalyst biotechs (CAPR, AGEN, CADL) offer event-driven upside. Today's strongest setups pair elevated short interest with a hard binary catalyst, not just a stale borrow print.
Read the report → - October 9, 2026
Squeeze Report — October 9, 2026
The tape is crowded with high-short-interest biotechs, but the fuel is mostly cheap and the options market has already pre-paid for the move. The more interesting setups are the event-driven consumer and industrial names where a real catalyst—earnings, a sale closing, or a strategic stake—could force actual covering.
Read the report → - October 8, 2026
Squeeze Report — October 8, 2026
Three names cluster around the same catalyst — Q3 earnings in early November — but the setups diverge sharply. PCOR and HOG offer mechanically real short bases with fundamental floors, while RLAY and SATL pair elevated short interest with active dilution that can absorb any squeeze.
Read the report → - October 7, 2026
Squeeze Report — October 7, 2026
Today's tape is crowded with biotech shorts, but the squeeze signals are decaying even where short interest is highest. BEAM and TGTX stand out as the only setups where positioning stress is still building, not bleeding, while names like REPL and ACHC show headline-grabbing SI that's quietly unwinding.
Read the report → - October 6, 2026
Squeeze Report — October 6, 2026
The tape is heavy with biotech short-interest setups, but almost none carry real borrow pressure — cheap locates and stale prints blunt the squeeze case. INOD and TNGX stand out for having near-term binary catalysts that could actually force covering, while GRND's buyback offers the only genuine float-shrink story.
Read the report → - October 5, 2026
Squeeze Report — October 5, 2026
TNGX tops the short-squeeze leaderboard for October 5, 2026 with 39% of its float sold short. 1 name scored in the hot zone (≥80) across 15 ranked tickers.
Read the report → - October 2, 2026
Squeeze Report — October 2, 2026
Six mid-tier setups, none screaming. The biotech cluster (TGTX, PGEN, ORIC, RLAY) shares cheap borrow and fading sector momentum, while QUBT and TDC offer more idiosyncratic risk — one a fundamentally hollow story, the other an earnings-dependent value trap.
Read the report → - October 1, 2026
Squeeze Report — October 1, 2026
Catalyst-driven setups dominate today: GLUE faces a binary Phase 1 readout this morning, PSKY approaches an Oct 6 merger close, and SATL nears a launch. Elsewhere, crowded short books like IBRX and GEMI keep colliding with heavy dilution, capping squeeze odds.
Read the report → - September 30, 2026
Squeeze Report — September 30, 2026
The tape splits into two crowded trades: high-days-to-cover biotechs waiting on November earnings (HALO, TNGX, SRPT) and heavily shorted names where borrow is cheap and shorts aren't stressed. The interesting setups are the ones where a hard catalyst meets a real fundamental edge — HALO's buyback-plus-guidance-raise and SGRY's completed divestiture stand out.
Read the report → - September 29, 2026
Squeeze Report — September 29, 2026
Biotech and crypto-adjacent small caps dominate today's most crowded shorts, but the real tension is between dense catalyst calendars and easy borrow. Names like GLUE, NVAX, and RLAY show heavy short interest yet still lack the financing pressure that forces covering.
Read the report → - September 28, 2026
Squeeze Report — September 28, 2026
The squeeze screen is crowded but conviction is thin: high short interest is everywhere, yet cheap borrow and stale data blunt most setups. The real tension sits in names like CHPT and ULCC, where violent momentum or crowded shorts collide with deteriorating balance sheets and insider selling.
Read the report → - September 25, 2026
Squeeze Report — September 25, 2026
Three high-conviction squeeze candidates cluster around late-September earnings: CNXC, SEI, and a crowded biotech tape. Elsewhere, catalysts are thinner — several high-short-interest names are fighting dilution overhangs and cheap borrow that blunt any forced-covering edge.
Read the report → - September 24, 2026
Squeeze Report — September 24, 2026
Short bases are elevated across the screen, but the mechanics are mostly missing: cheap borrow, ample availability, and insider selling dominate. VERA and SYM hold the most compelling structural profiles, while PCT and REPL show that high SI alone doesn't guarantee a squeeze.
Read the report → - September 23, 2026
Squeeze Report — September 23, 2026
The tape is crowded with high-short-interest names where the float is tight but the borrow is cheap—a setup that rewards catalyst-triggered pops, not structural squeezes. SailPoint and Tango stand out for having real near-term events, while the energy names (AESI, CRK) look like value traps wearing squeeze costumes.
Read the report → - September 22, 2026
Squeeze Report — September 22, 2026
The tape splits cleanly today: a cluster of high-short biotechs with real catalysts — CADL's ASTRO data, SVRA's PDUFA, SRPT's FDA action — against a broader field of stale-SI, dilution-heavy names where the squeeze math only works on paper. The edge is in knowing which profile you're actually trading.
Read the report → - September 21, 2026
Squeeze Report — September 21, 2026
ACHC tops the short-squeeze leaderboard for September 21, 2026 with 26% of its float sold short. 1 name scored in the hot zone (≥80) across 15 ranked tickers.
Read the report → - September 18, 2026
Squeeze Report — September 18, 2026
The tape is bifurcated: distressed consumer and balance-sheet-heavy names (PLAY, CLBK, NVAX) are setting up purely on technical short-covering fuel, while momentum tech (SDGR, SOUN) is fighting against shorts already heading for the exits. The cleanest gamma is absent almost everywhere — options markets are inert across the board.
Read the report → - September 17, 2026
Squeeze Report — September 17, 2026
The short-squeeze tape is bifurcating: crowded biotech shorts (ABEO, ORIC, SMMT) are getting a bid from a fresh healthcare rotation, while high-float names in energy and REITs are losing the sector tailwind. The real tells today are borrow costs and share availability—most of these setups have cheap borrow and no forced-covering pressure, making them catalyst-dependent rather than structural squee
Read the report → - September 16, 2026
Squeeze Report — September 16, 2026
Biotech dominates today's squeeze screen, but most setups are already partially unwound — shorts are covering into strength, not trapped. The real edge is in names where binary FDA or data catalysts could force violent covering despite cheap borrow.
Read the report → - September 15, 2026
Squeeze Report — September 15, 2026
Short interest is elevated across the tape, but the borrow market is telling a different story: fees are uniformly cheap and shares are available, meaning today's squeeze candidates are catalyst bets, not structural traps. The notable exception is IBRX, where short interest exceeds the entire float, yet a going-concern warning and active ATM keep it a lottery ticket.
Read the report → - September 14, 2026
Squeeze Report — September 14, 2026
The tape splits between biotech catalysts — SRPT's FDA action, TNGX's ESMO readout — and leveraged crypto treasury shorts still pressing into ASST, DFDV and SBET strength. The cleanest setups cluster where high days-to-cover meets a hard binary date, not a technical bounce.
Read the report → - September 11, 2026
Squeeze Report — September 11, 2026
The tape is crowded with fragile, medium-conviction squeeze candidates, but the real story is the clustering of binary catalysts: CELC's REVTORPYK launch, VERA's ORIGIN 3 readout, and SMMT's ivonescimab PDUFA all land within weeks. The setups are live, but dilution overhangs and cheap borrow are the recurring killjoys.
Read the report → - September 10, 2026
Squeeze Report — September 10, 2026
The tape splits cleanly today: crowded biotech shorts (GLUE, SLS, SNDX, IRD) are pressing against heavy dilution overhangs, while crypto-treasury names (DFDV, SBET, ASST) show short interest already rolling over after big runs. The real tension is whether tight floats can overcome supply walls before catalysts land.
Read the report → - September 9, 2026
Squeeze Report — September 9, 2026
The tape is crowded with high-short-interest biotechs and broken balance sheets, but the real signal is divergence: NVAX and SRPT are already squeezing while shorts quietly cover, leaving GRPN and XXI as the most fragile float squeezes. The catalyst calendar is thin until late September, so positioning—not news—is driving these names.
Read the report → - September 8, 2026
Squeeze Report — September 8, 2026
The tape is crowded with high-short-interest names, but conviction is scarce: cheap borrow and dilution overhangs are capping most setups. CHPT and ORIC stand out for having both hard squeeze data and near-term catalysts, while the energy complex (UUUU, AESI, CRK) is the only sector cluster showing rotation tailwinds.
Read the report → - September 7, 2026
Squeeze Report — September 7, 2026
Biotech dominates today's squeeze screen, but the setups are mostly pre-paid: crowded options, cheap borrow, and heavy dilution overhangs cap upside across SLS, SRPT, TGTX, and AMLX. The more interesting tension sits in GRRR, where a 40% short interest and rising borrow costs collide with unresolved fraud allegations.
Read the report → - September 4, 2026
Squeeze Report — September 4, 2026
The tape is bifurcated: energy and AI-adjacent names with hard catalysts (CRK, AI) are drawing real squeeze interest, while a crowded biotech cohort (SLDB, ORIC, GLUE, PHAT) screens hot on short interest but is fighting dilution overhangs and a sector rotation that keeps conviction capped.
Read the report → - September 3, 2026
Squeeze Report — September 3, 2026
Biotech dominates today's high-conviction squeeze watch, but the setups are bifurcated: TGTX and VIR show shorts pressing into strength near 52-week highs, while TNGX and UNCY carry extreme short interest undermined by cheap borrow and heavy ATM overhang. The real story is how many of these 'squeeze' candidates are already seeing shorts cover.
Read the report → - September 2, 2026
Squeeze Report — September 2, 2026
Biotech dominates today's high-conviction squeeze candidates, with FDA decisions and Phase 3 readouts clustering as the catalysts most likely to force covering. Outside the sector, GRRR's 26.85% borrow fee and CRK's $1.65B asset sale stand out as the only non-biotech setups with real teeth.
Read the report → - September 1, 2026
Squeeze Report — September 1, 2026
The tape is crowded with high-short-interest names that look better on a screener than in the borrow book. The real story is the gap between headline short interest and actual covering pressure — shorts are already exiting several of these setups, and cheap borrow plus dilution overhangs are capping the upside.
Read the report → - August 31, 2026
Squeeze Report — August 31, 2026
SLDB tops the short-squeeze leaderboard for August 31, 2026 with 22% of its float sold short. 1 name scored in the hot zone (≥80) across 15 ranked tickers.
Read the report →